|
“Collaboration in Cancer Drug Trials: Targets, Biomarkers, and Drugs” was held in Boston, Massachusetts, on November 1-2, 2010.
“Collaboration in Cancer Drug Trials: Targets, Biomarkers, and Drugs,” presented in collaboration with Massachusetts General Hospital Cancer Center and The Oncologist, focused on personalized cancer care, with three major themes: new targeted agents, strategies for profiling and selection of patients for targeted drug trials, and biomarkers and animal models to guide clinical development.
Hosted by: Brought to you in partnership with
“…The meeting was beyond informative. It was inspiring."
--John Heneghan, Postdoctoral Fellow, Beth Israel Deaconess Medical Center
To download a copy of the presentation abstract book, click here.
DISCLAIMER
View a presentation given at the meeting by clicking the image below.
Session 1
Selecting a target in cancer therapeutics:
personalizing cancer therapy
|
 Collaboration in Cancer Drug Trials: Targets, Biomarkers, and Drugs
Martin J. Murphy, DMedSc, PhD |
 Targeting critical oncogenic pathways in cancer - emerging molecules and translational strategies
William Sellers, MD |
 The PI3K pathway
Lewis Cantley, PhD |
 DNA Repair Enzymes as Therapeutic Targets in Breast Cancer
Joyce O'Shaughnessy, MD |
Session 2
Selecting a target in cancer therapeutics:
personalizing cancer therapy
|
 BRAF: the first prevalent oncogene target to show single-agent responsiveness
Keith Flaherty, MD |
 The ALK story, a new kind of phase 1 trial
Alice Shaw, MD, PhD |
 Biomarker-driven drug development: from dream to reality
Mace Rothenberg, MD |
Session 3
Biomarkers
|
 2010 Bob Pinedo Cancer Care Prize Award
H.M. Pinedo, MD, PhD |
 2010 Pinedo Cancer Care Prize Award and Keynote Address
Jose Baselga, MD, PhD |
 Finding biomarkers: molecular profiling and CTCs
Daniel Haber, MD, MS, PhD |
 The use of emerging genomic technologies to predict tumor response and drug resistance
Levi Garraway, MD, PhD |
|
Session 4
New Targets
|
 Protein Methyl Transferases as a Novel Target Class for Molecularly Targeted Cancer Therapy
Robert A. Copeland, PhD |
 ERBB3
David Livingston, MD |
 Novel strategies for drug development in cancer: an industry perspective
Eric H. Rubin, MD |
|
Session 5
Disease specific drug development
|
 Oncogenomics to target myeloma in the bone marrow microenvironment
Kenneth C. Anderson, MD |
 Drug discovery for rare diseases: The ACCRF Model
Jeff Kaufman |
 Neuroblastoma immunotherapy
Paul M. Sondel, MD, PhD |
|
Session 6
Animal Models
|
 Zebrafish as a model for human cancer
Leonard Zon, MD |
 A coding-independent function of gene and pseudogene mRNAs regulates tumor biology
Pier Paolo Pandolfi, MD, PhD |
 Modeling ras
Tyler Jacks, PhD |
The meeting was well attended by physicians and researchers in academic and practice settings who wish to advance their current knowledge of the discovery process and clinical cancer medicine as well as industry representatives interested in exploring the potential for collaboration between academia and industry.
Acknowledgement
Supported by educational grants from
|
